Effectiveness and Safety of Atelocollagen in the Management of Chronic Non-specific Low Back Pain
Study Details
Study Description
Brief Summary
The purpose of this study was to evaluate the effectiveness and safety of atelocollagen in the management of chronic low back pain with sarcopenia due to degenerative changes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Patients with chronic low back pain are enrolled and divided into group A (atelocollagen) and group B (control) through randomization after obtaining informed consent.
Investigators record tender points for the multifidus, erector spinae, and quadratus lumborum muscles by physical examination.
Investigators evaluate each muscle using ultrasound according to the assignment of each group, and apply atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) or local anesthetics only (normal saline 3 mL + 1% lidocaine 3 mL) to each muscle on both sides.
The subject of the study performs a total of 3 injections at intervals of 2 weeks, and each measurement variable is collected by visiting 4 weeks and 12 weeks after the last injection.
Changing medications or additive interventions are not allowed before 4 weeks after last injection. Only acetaminophen is allowed as a rescue drug.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Control Group 1% licocaine 3 mL + Normal saline 3 mL mixture |
Device: atelocollagen
This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.
Patients with chronic low back pain are randomized after obtaining informed consent for the study.
Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.
After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.
Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).
Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL).
|
| Experimental: Atelocollagen group 1% lidocaine 3 mL + atelocollagen 3 mL mixture |
Device: atelocollagen
This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.
Patients with chronic low back pain are randomized after obtaining informed consent for the study.
Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.
After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.
Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).
Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL).
|
Outcome Measures
Primary Outcome Measures
- Pain changes in low back pain [4 weeks after last intervention]
The changes of the 11-point Numeric Rating Scale(NRS) pain score (numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")) after intervention between two groups.
Secondary Outcome Measures
- Pain changes in low back pain [12 weeks after last intervention]
The changes of the 11-point Numeric Rating Scale(NRS) pain score (numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can i
- Cross-sectional area [4, 12 weeks after last intervention]
The changes of cross-sectional area using ultrasound after intervention between two groups.
- Oswestry Disability Index(ODI) score [4, 12 weeks after last intervention]
The changes of ODI score after intervention between two groups.
- Satisfaction (participants) [4 weeks after first intervention]
5-pointed satisfaction scale of intervention (participants)
- Satisfaction (pain physician) [4 weeks after first intervention]
5-pointed satisfaction scale of intervention (pain physician)
- Pain related to intervention [4 weeks after first intervention]
The 11-point Numeric Rating Scale(NRS) pain score (numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")) related to intervention
- Medication [12 weeks after last intervention]
The changes in medication
Eligibility Criteria
Criteria
Inclusion Criteria:
- Non-specific low back pain with persistent paraspinal tenderness of NRS 4 or higher despite conservative treatment (including physical therapy, exercise therapy, oral drug administration, and epidural block) for at least 3 months.
Adults 19 years of age or older
Exclusion Criteria:
- Systemic or local infection Coagulopathy Patients whose structure is difficult to confirm on ultrasound due to significant deformity of the lumbar spine Neoplasm of spine Cognitive disorder Patients with hypersensitivity to local anesthetics or amide-based local anesthetics Patients those who are allergic to or sensitive to atelocollagen ingredients or pork Women who are pregnant, lactating, or planning to become pregnant during the clinical period, or women of childbearing age who are not using available contraceptive methods Those who participated in other clinical trials within 30 days prior to screening or 5 times the half-life of the investigational drug in the clinical trial in which they participated, whichever is longer, whichever is longer Patients with serious systemic diseases
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Seoul National University Hospital | Seoul | Korea, Republic of |
Sponsors and Collaborators
- Seoul National University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2011-183-1177